Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Vivera Pharmaceuticals Congratulates Clinical Research Partner, Parexel International, on its $8.5 Bil Acquisition

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Vivera Pharmaceuticals, Inc., congratulates its clinical research partner, Parexel International, on its $8.5 billion acquisition. The EQT IX fund and the private equity business within Goldman Sachs Asset Management recently agreed to purchase the clinical research organization and biopharmaceutical company.

Parexel is a leading global provider of clinical research and consulting services to the pharmaceutical and biotech industries. Known and operating worldwide, Parexel provides comprehensive drug development services, including clinical trial, regulatory, and market access services. With Parexel’s expertise, the pharmaceutical and biotechnology industry can deliver therapeutic solutions to the market both quickly and cost-effectively.

Parexel has been instrumental in providing clinical development strategy and planning for Vivera’s first Investigational New Drug (IND) Application and is following the clinical trial process through completion. To accelerate the development and commercialization of innovative therapies formulated with TABMELT®, Vivera’s licensed patented and patent-pending sublingual drug system, Parexel has been key in organizing, designing, and facilitating the clinical process.

“Vivera is part of a new age of pharmaceutical companies investing in research and development in pursuit of a transformational approach to patient treatment by providing safer alternatives to existing medications,” stated Paul Edalat, Chairman and CEO of Vivera Pharmaceuticals. “Our partnership with Parexel promises that the historically complex route for medications from clinical trials to patient access is organized while supporting safety, efficacy, and value for the patient.”

Vivera’s product pipeline includes oral medications and medications formulated in the TABMELT® sublingual drug delivery system. By bringing innovative new drugs to market through the clinical trial and commercial process, Vivera’s clinical research partnership with Parexel will offer new medication management options to patients and health care providers.

“Our experience working with Parexel has been a positive one,” said Dr. Stephen J. McColgan, Vivera’s Chief Medical Officer. “Their team has done a good job guiding Vivera through the clinical research process. With their direction, we are more efficiently bringing novel medications to treat a variety of indications using the TABMELT® delivery system to market.”

The Company is proud to be working with Parexel, and supports the value Parexel continues to provide to the health care industry and patients beyond its well-deserved valuation.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine